# Cmvalue

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cmvalue

- Industry: Healthcare IT
- Headquarters: Hangzhou, China
- Website: www.cmvalue.com
- Latest round: Series A (Apr 7, 2021)
- Investors on record: 2

## About

Based in China, Cmvalue is a medical service provider specializing in digital healthcare solutions aimed at enhancing clinical workflows and patient engagement across various disease domains.Cmvalue, founded in 2020 and headquartered in Hangzhou, China, operates in the digital healthcare sector. The company has engaged in 2 deals, with its most recent deal occurring on April 7, 2021. It was founded to address the needs of healthcare providers through innovative solutions in the medical industry.Yongliu Technology, a division of Cmvalue, specializes in digital healthcare solutions for vertical disease domains. Their key offerings include advanced platforms that optimize clinical workflows and enhance patient engagement, focusing on disease management, patient monitoring, and treatment optimization for healthcare providers.Yongliu Technology generates revenue primarily through subscription-based models and strategic partnerships with healthcare institutions. Transactions are conducted on a B2B basis, with healthcare providers subscribing to their services for access to specialized platforms. Revenue is accrued via annual licensing fees that vary by implementation scale and service scope.Following its SERIES A funding led by Sequoia Capital in April 2021, Cmvalue aims to develop new products targeting enhanced patient monitoring solutions, with a launch planned for late 2023. The company also plans to expand into various urban areas in China, leveraging its recent funding to support these initiatives and increase its footprint in the digital healthcare market.

## Funding rounds

- Series A, Apr 7, 2021 — Hong Shan, Marathon Venture Partners
- Angel, Dec 7, 2020 — Marathon Venture Partners

## Investors

- Marathon Venture Partners (https://capitalatlas.ai/funds/marathon-venture-partners) — Angel, Series A
- Hong Shan — Series A